vs
Side-by-side financial comparison of Cinemark Holdings, Inc. (CNK) and Revvity (RVTY). Click either name above to swap in a different company.
Cinemark Holdings, Inc. is the larger business by last-quarter revenue ($776.3M vs $772.1M, roughly 1.0× Revvity). Revvity runs the higher net margin — 12.7% vs 4.4%, a 8.3% gap on every dollar of revenue. On growth, Revvity posted the faster year-over-year revenue change (5.9% vs -4.7%). Over the past eight quarters, Cinemark Holdings, Inc.'s revenue compounded faster (15.8% CAGR vs 9.0%).
Cinemark Holdings, Inc. is an American movie theater chain that started operations in 1977 and since then has operated theaters with hundreds of locations throughout the Americas. It is headquartered in Plano, Texas, in the Dallas–Fort Worth area. Cinemark operates 497 theaters and 5,653 screens in the U.S. and Latin America as of March 2025. It is also the largest movie theater chain in Brazil, with a 30 percent market share.
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
CNK vs RVTY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $776.3M | $772.1M |
| Net Profit | $34.1M | $98.4M |
| Gross Margin | — | — |
| Operating Margin | — | 14.5% |
| Net Margin | 4.4% | 12.7% |
| Revenue YoY | -4.7% | 5.9% |
| Net Profit YoY | -33.5% | 3.9% |
| EPS (diluted) | $0.33 | $0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $776.3M | $772.1M | ||
| Q3 25 | $857.5M | $698.9M | ||
| Q2 25 | $940.5M | $720.3M | ||
| Q1 25 | $540.7M | $664.8M | ||
| Q4 24 | $814.3M | $729.4M | ||
| Q3 24 | $921.8M | $684.0M | ||
| Q2 24 | $734.2M | $691.7M | ||
| Q1 24 | $579.2M | $649.9M |
| Q4 25 | $34.1M | $98.4M | ||
| Q3 25 | $49.5M | $46.7M | ||
| Q2 25 | $93.5M | $53.9M | ||
| Q1 25 | $-38.9M | $42.2M | ||
| Q4 24 | $51.3M | $94.6M | ||
| Q3 24 | $187.8M | $94.4M | ||
| Q2 24 | $45.8M | $55.4M | ||
| Q1 24 | $24.8M | $26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
| Q4 25 | 4.4% | 12.7% | ||
| Q3 25 | 5.8% | 6.7% | ||
| Q2 25 | 9.9% | 7.5% | ||
| Q1 25 | -7.2% | 6.4% | ||
| Q4 24 | 6.3% | 13.0% | ||
| Q3 24 | 20.4% | 13.8% | ||
| Q2 24 | 6.2% | 8.0% | ||
| Q1 24 | 4.3% | 4.0% |
| Q4 25 | $0.33 | $0.86 | ||
| Q3 25 | $0.40 | $0.40 | ||
| Q2 25 | $0.63 | $0.46 | ||
| Q1 25 | $-0.32 | $0.35 | ||
| Q4 24 | $0.36 | $0.77 | ||
| Q3 24 | $1.19 | $0.77 | ||
| Q2 24 | $0.32 | $0.45 | ||
| Q1 24 | $0.19 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $919.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $7.3B |
| Total Assets | — | $12.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | — | $7.3B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | — | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.9B | ||
| Q2 24 | — | $7.9B | ||
| Q1 24 | — | $7.8B |
| Q4 25 | — | $12.2B | ||
| Q3 25 | — | $12.1B | ||
| Q2 25 | — | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | — | $12.4B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $13.4B | ||
| Q1 24 | — | $13.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $182.0M |
| Free Cash FlowOCF − Capex | — | $161.8M |
| FCF MarginFCF / Revenue | — | 21.0% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | — | 1.85× |
| TTM Free Cash FlowTrailing 4 quarters | — | $509.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $182.0M | ||
| Q3 25 | — | $138.5M | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | — | $174.2M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $158.6M | ||
| Q1 24 | — | $147.6M |
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CNK
| Admissions Revenue | $383.8M | 49% |
| Concessions | $302.4M | 39% |
| Other Revenue | $37.5M | 5% |
| Transferred Over Time | $28.2M | 4% |
| Screen Advertising Screen Rental And Promotional Revenues | $24.4M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
